Pentagon Rolls Out Mandatory Testosterone Screening for Troops Over 30 — Then Paused

The Pentagon this week made good on a promise from Defense Secretary Pete Hegseth to overhaul how the military approaches troop health, issuing new clinical guidelines mandating testosterone deficiency screening for male service members age 30 and older. The policy took effect immediately, only for the department to temporarily rescind the guidance just one day later, underscoring how fast the Trump administration is moving to reshape military readiness policy, sometimes faster than its own bureaucracy can keep up with.

The Defense Health Agency issued the guidelines on Wednesday, formally implementing a directive Hegseth first announced back in July. Under the new policy, male active-duty and reserve service members age 30 and older will undergo mandatory testosterone blood tests as part of their regular periodic health assessments. Younger men will only be tested if they request it themselves or if a clinician identifies specific warning signs.

Hegseth framed the initiative as a matter of basic readiness and long-term health for the men and women who serve. “Taking care of your long-term health means ensuring you remain strong, resilient and capable, not just for your next deployment, but for the rest of your life, so you can thrive long after you take off the uniform,” he said when he first announced the program over the summer.

The secretary has been blunt about his reasoning. He has said the goal is to make sure troops “have the right testosterone levels to operate at your absolute best,” a straightforward, common-sense justification that fits squarely within the administration’s broader push to rebuild a leaner, tougher, more physically capable fighting force after years of what critics on the right have described as a military distracted by social engineering projects instead of combat readiness.

Under the guidelines, service members found to have clinically low testosterone, a condition known as hypogonadism, will be offered further evaluation and, if appropriate, voluntary hormone replacement therapy. Importantly, the screening itself is mandatory, but no one is being forced into treatment. The choice of whether to pursue hormone therapy remains entirely up to the individual service member.

The policy also draws a firm line that should reassure skeptics worried about performance-enhancing drug abuse creeping into the ranks. Testosterone use for non-medical purposes, including any attempt at performance enhancement without a legitimate doctor’s prescription, remains strictly prohibited in the military. This is about identifying and treating a legitimate medical deficiency, not handing out steroids.

Women in the military are handled differently under the new guidance. They will not be subject to routine, mandatory testosterone blood tests. Instead, providers have been directed to screen female service members for symptoms such as fatigue and disrupted menstrual cycles that can be linked to low energy availability and related conditions. In certain cases involving postmenopausal women experiencing low sexual desire, guidelines are in place for prescribing off-label testosterone treatment.

The rollout of the policy generated plenty of buzz across conservative media, with commentators framing it as part of a broader cultural shift at the Pentagon under Hegseth’s leadership, a shift away from what they characterize as a woke-driven focus during the previous administration and toward a renewed emphasis on physical strength and lethality. Fox News commentators joked about the department moving its focus from pronouns to protein, a lighthearted jab at the priorities of the prior Pentagon leadership.

Not everyone in the medical community has been quick to cheer the announcement, and fairness requires acknowledging that pushback. Some physicians quoted in coverage of the new guidelines expressed skepticism that universal testosterone screening for men over 30 is grounded in strong scientific evidence. Their concern is that testing large numbers of asymptomatic troops could lead to unnecessary treatment and additional costs without a clear, proven benefit to combat readiness.

Doctors interviewed following the announcement noted there is limited evidence that broad, population-level testosterone screening actually improves military readiness in a measurable way, and cautioned that treating men who show no outward symptoms of low testosterone could expose the force to needless medical intervention.

Despite that skepticism from parts of the medical establishment, the timing of the rollout appears tied to a broader national conversation. The policy was reportedly finalized just ahead of a scheduled meeting of Food and Drug Administration experts, suggesting the Pentagon wanted its own guidance in place before any wider regulatory discussion around testosterone therapy takes place at the federal level.

Then came the twist. Just one day after the guidelines took effect, the Department of Defense announced it was temporarily rescinding the mandatory testosterone screening guidance altogether. The abrupt reversal, confirmed by multiple outlets on Wednesday into Thursday, left plenty of questions about what exactly prompted the pause, whether it was a matter of implementation logistics, further legal review, or simply an internal recalibration of how the rollout should proceed.

Whatever the reason for the pause, it is worth noting that the underlying policy direction from Hegseth has not changed. This is not the administration backing away from the broader goal of prioritizing troop health and physical readiness. It appears instead to be a temporary procedural step, and there is every indication the screening program will return in some form once the department works through whatever prompted the rescission.